CXCR4 and neoplasm: A peer group of researchers and investigators investigated the effect of thymoquinone with different doses (2 and 4 mg/kg) dose‐dependently against MDA‐MB‐231 triple negative breast cancer in experimental mouse via inhibiting CXCR4 expression, tumor growth, and tumor vascularity along with suppressing the brain, lung, and bone metastases.